

Roberta Donadelli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7885507/roberta-donadelli-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36
papers

3,282
citations

23
h-index

37
g-index

37
ext. papers

3,673
ext. citations

8.1
avg. IF

4.03
L-index

#	Paper	IF	Citations
36	SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation.. <i>Frontiers in Immunology</i> , 2022 , 13, 827146	8.4	7
35	and Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. <i>Frontiers in Genetics</i> , 2021 , 12, 670727	4.5	1
34	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study.. <i>PLoS ONE</i> , 2021 , 16, e0261113	3.7	4
33	Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. <i>Frontiers in Immunology</i> , 2019 , 10, 853	8.4	15
32	An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. <i>American Journal of Kidney Diseases</i> , 2019 , 74, 56-72	7.4	36
31	Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. <i>Pediatric Nephrology</i> , 2019 , 34, 1311-1323	3.2	20
30	Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. <i>Frontiers in Immunology</i> , 2018 , 9, 2329	8.4	15
29	Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. <i>Journal of Immunology</i> , 2017 , 199, 1021-1040	5.3	37
28	ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 2002-12	6.9	9
27	Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 1011-9	6.9	39
26	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. <i>Blood</i> , 2014 , 124, 1715-26	2.2	220
25	Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 2053-65	12.7	74
24	ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy. <i>Diabetes</i> , 2013 , 62, 3599-609	0.9	23
23	Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. <i>Blood</i> , 2012 , 120, 440-8	2.2	91
22	MYO1E mutations and childhood familial focal segmental glomerulosclerosis. <i>New England Journal of Medicine</i> , 2011 , 365, 295-306	59.2	195
21	Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 1844-59	6.9	661
20	Mutations in FN1 cause glomerulopathy with fibronectin deposits. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 2538-43	11.5	96

19	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. <i>Thrombosis and Haemostasis</i> , 2006 , 96, 454-464	7	64
18	Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood. <i>Blood</i> , 2006 , 107, 1943-50	2.2	58
17	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. <i>Thrombosis and Haemostasis</i> , 2006 , 96, 454-64	7	16
16	Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16, 1177-83	12.7	116
15	Diverse Functional Implications of ADAMTS13 Gene Mutations in Patients with TTP and Congenital Deficiency.. <i>Blood</i> , 2004 , 104, 513-513	2.2	2
14	Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein kinase-dependent pathways. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 2436-46	12.7	105
13	Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. <i>Kidney International</i> , 2002 , 62, 846-56	9.9	94
12	Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis. <i>American Journal of Pathology</i> , 2002 , 161, 2179-93	5.8	116
11	Protein traffic activates NF-kB gene signaling and promotes MCP-1-dependent interstitial inflammation. <i>American Journal of Kidney Diseases</i> , 2000 , 36, 1226-41	7.4	134
10	Xenogeneic serum promotes leukocyte-endothelium interaction under flow through two temporally distinct pathways: role of complement and nuclear factor-kappaB. <i>Journal of the American Society of Nephrology: JASN</i> , 1999 , 10, 2197-207	12.7	20
9	Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. <i>Kidney International</i> , 1998 , 53, 726-34	9.9	63
8	Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. <i>Kidney International</i> , 1998 , 53, 1608-15	9.9	324
7	Identification of a novel gene--SSK1--in human endothelial cells exposed to shear stress. <i>Biochemical and Biophysical Research Communications</i> , 1998 , 246, 881-7	3.4	6
6	The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. <i>American Journal of Kidney Diseases</i> , 1997 , 29, 254-64	7.4	67
5	Fluid Shear Stress Modulates von Willebrand Factor Release From Human Vascular Endothelium. <i>Blood</i> , 1997 , 90, 1558-1564	2.2	110
4	Fluid Shear Stress Modulates von Willebrand Factor Release From Human Vascular Endothelium. <i>Blood</i> , 1997 , 90, 1558-1564	2.2	5
3	Systemic and fetal-maternal nitric oxide synthesis in normal pregnancy and pre-eclampsia. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1996 , 103, 879-86	3.7	51
2	Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. <i>Circulation Research</i> , 1995 , 76, 536-43	15.7	371

- 1 Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. *Kidney International*, **1992**, 42, 981-90

9.9 17